(Q38536939)

English

Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis

scientific article published on 24 June 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

0 references

1 reference

Europe PubMed Central

Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

bipolar disorder

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

Christoph Correll

5

object named as

Christoph U Correll

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Britta Galling

1

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Maryam A Garcia

2

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Uzoma Osuchukwu

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Katsuhiko Hagi

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

language of work or name

0 references

publication date

24 June 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Expert Opinion on Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1181-1199

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

National trends in psychotropic medication polypharmacy in office-based psychiatry

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Comorbid medical illness in bipolar disorder

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Comorbidities and mortality in bipolar disorder: a Swedish national cohort study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Comorbidity in bipolar disorder: a framework for rational treatment selection

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Pattern of pharmacotherapy by episode types for patients with bipolar disorders and its concordance with treatment guidelines.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Overview of antidepressant treatment of bipolar depression

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Clinically significant pharmacokinetic drug interactions with carbamazepine. An update

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Metabolic drug interactions with newer antipsychotics: a comparative review.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1053457

21 January 2018

Identifiers

10.1517/14740338.2015.1053457

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38536939&oldid=1766238180"